Aging does not impact safety and efficacy of biologic or targeted synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
Abstract Background The study compared biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) efficacy and safety in elderly rheumatoid arthritis (RA) patients over a period of 1 year. Results This retrospective study included 52 RA patients. At baseline elderly pati...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-06-01
|
| Series: | Egyptian Rheumatology and Rehabilitation |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43166-025-00336-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850224242005639168 |
|---|---|
| author | Yasemin Tombak Ajda Bal Emel Eksioglu Nihan Abidin Ozgur Zeliha Karaahmet Deniz Dulgeroglu |
| author_facet | Yasemin Tombak Ajda Bal Emel Eksioglu Nihan Abidin Ozgur Zeliha Karaahmet Deniz Dulgeroglu |
| author_sort | Yasemin Tombak |
| collection | DOAJ |
| description | Abstract Background The study compared biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) efficacy and safety in elderly rheumatoid arthritis (RA) patients over a period of 1 year. Results This retrospective study included 52 RA patients. At baseline elderly patients had longer disease duration, more comorbidities and extraarticular involvement, and previously used conventional synthetic (cs) DMARDs (p < 0.05). A statistically significant change from baseline was observed in the 6th and 12th months regarding Disease Activity Score (DAS-28) and the Health Assessment Questionnaire (HAQ) scores were observed in both groups following treatment with bDMARDs/tsDMARD (p < 0.000). These changes in DAS-28 and HAQ scores were similar in both groups and showed no statistical difference between groups (p = 0.974 and p = 0.578 respectively). Also, no differences were observed between the groups with respect to the percentage of good, moderate or non-responders according to European Alliance of Associations for Rheumatology response criteria. Similarly, no differences were found between groups regarding severe adverse events, drug discontinuation or switch rates. Conclusion The efficacy and adverse effects of bDMARDs/tsDMARD were similar in elderly and younger RA patients. Both bDMARDs and tsDMARD are efficacious and safe for use in elderly RA patients. |
| format | Article |
| id | doaj-art-4557e757ff8a4fccb605f38891d1f15e |
| institution | OA Journals |
| issn | 2090-3235 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Egyptian Rheumatology and Rehabilitation |
| spelling | doaj-art-4557e757ff8a4fccb605f38891d1f15e2025-08-20T02:05:41ZengSpringerOpenEgyptian Rheumatology and Rehabilitation2090-32352025-06-015211810.1186/s43166-025-00336-2Aging does not impact safety and efficacy of biologic or targeted synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritisYasemin Tombak0Ajda Bal1Emel Eksioglu2Nihan Abidin3Ozgur Zeliha Karaahmet4Deniz Dulgeroglu5Ankara Etlik City HospitalAnkara Etlik City HospitalAnkara Etlik City HospitalHayat HospitalAnkara Etlik City HospitalDiskapi Yildirim Beyazit Education and Research HospitalAbstract Background The study compared biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) efficacy and safety in elderly rheumatoid arthritis (RA) patients over a period of 1 year. Results This retrospective study included 52 RA patients. At baseline elderly patients had longer disease duration, more comorbidities and extraarticular involvement, and previously used conventional synthetic (cs) DMARDs (p < 0.05). A statistically significant change from baseline was observed in the 6th and 12th months regarding Disease Activity Score (DAS-28) and the Health Assessment Questionnaire (HAQ) scores were observed in both groups following treatment with bDMARDs/tsDMARD (p < 0.000). These changes in DAS-28 and HAQ scores were similar in both groups and showed no statistical difference between groups (p = 0.974 and p = 0.578 respectively). Also, no differences were observed between the groups with respect to the percentage of good, moderate or non-responders according to European Alliance of Associations for Rheumatology response criteria. Similarly, no differences were found between groups regarding severe adverse events, drug discontinuation or switch rates. Conclusion The efficacy and adverse effects of bDMARDs/tsDMARD were similar in elderly and younger RA patients. Both bDMARDs and tsDMARD are efficacious and safe for use in elderly RA patients.https://doi.org/10.1186/s43166-025-00336-2bDMARDsElderlyEULARHAQRheumatoid arthritisSafety of DMARDs |
| spellingShingle | Yasemin Tombak Ajda Bal Emel Eksioglu Nihan Abidin Ozgur Zeliha Karaahmet Deniz Dulgeroglu Aging does not impact safety and efficacy of biologic or targeted synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis Egyptian Rheumatology and Rehabilitation bDMARDs Elderly EULAR HAQ Rheumatoid arthritis Safety of DMARDs |
| title | Aging does not impact safety and efficacy of biologic or targeted synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis |
| title_full | Aging does not impact safety and efficacy of biologic or targeted synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis |
| title_fullStr | Aging does not impact safety and efficacy of biologic or targeted synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis |
| title_full_unstemmed | Aging does not impact safety and efficacy of biologic or targeted synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis |
| title_short | Aging does not impact safety and efficacy of biologic or targeted synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis |
| title_sort | aging does not impact safety and efficacy of biologic or targeted synthetic disease modifying antirheumatic drugs in patients with rheumatoid arthritis |
| topic | bDMARDs Elderly EULAR HAQ Rheumatoid arthritis Safety of DMARDs |
| url | https://doi.org/10.1186/s43166-025-00336-2 |
| work_keys_str_mv | AT yasemintombak agingdoesnotimpactsafetyandefficacyofbiologicortargetedsyntheticdiseasemodifyingantirheumaticdrugsinpatientswithrheumatoidarthritis AT ajdabal agingdoesnotimpactsafetyandefficacyofbiologicortargetedsyntheticdiseasemodifyingantirheumaticdrugsinpatientswithrheumatoidarthritis AT emeleksioglu agingdoesnotimpactsafetyandefficacyofbiologicortargetedsyntheticdiseasemodifyingantirheumaticdrugsinpatientswithrheumatoidarthritis AT nihanabidin agingdoesnotimpactsafetyandefficacyofbiologicortargetedsyntheticdiseasemodifyingantirheumaticdrugsinpatientswithrheumatoidarthritis AT ozgurzelihakaraahmet agingdoesnotimpactsafetyandefficacyofbiologicortargetedsyntheticdiseasemodifyingantirheumaticdrugsinpatientswithrheumatoidarthritis AT denizdulgeroglu agingdoesnotimpactsafetyandefficacyofbiologicortargetedsyntheticdiseasemodifyingantirheumaticdrugsinpatientswithrheumatoidarthritis |